SCHEMBL5160397

SCHEMBL5160397

NCCNC[C@@H](N)CO

nearest known ligand 0.00

⚠ Novel chemotype — no close known analogue (best Tanimoto < 0.3). Unexplored chemical space relative to ChEMBL.

Similar compounds — the chemically nearest patent molecules

Nearest neighbours by Morgan-fingerprint cosine across the patent-compound collection, with each neighbour's top predicted target and the predicted targets it shares with this molecule.

Compoundsimilaritytop predictedshared targets
SCHEMBL8246840 1.00
Hydrochloric Acid SCHEMBL16114150 0.98 ANPEP (0.47)
Hydrochloric Acid SCHEMBL2439875 0.98 ANPEP (0.47)
Hydrochloric Acid SCHEMBL7055449 0.89 UBE2N (0.48)
Acetic Acid SCHEMBL5555720 0.88 ANPEP (0.44)
Acetic Acid SCHEMBL5555716 0.88 ANPEP (0.44)
SCHEMBL2781205 0.83 ANPEP (0.33)
SCHEMBL24660875 0.81 PKM (0.35)
SCHEMBL12952546 0.79 ANPEP (0.46)
SCHEMBL8044785 0.79 TDP1 (0.46)

Similarity is cosine over the 2,048-bit Morgan fingerprint (≈ Tanimoto). Identical fingerprints score 1.00.

Patent provenance — the patents this molecule appears in, and who filed them

Claimed or disclosed in 18 patents. claimed = in the patent's claims; disclosed = body only.

PatentTitleAssigneePublishedPriorityFilingCountryStatus
CN-107663228-B Nuclear magnetic resonance imaging compound, nuclear magnetic resonance imaging agent and application thereof, and nuclear magnetic resonance imaging method 北京市神经外科研究所 2021-01-19 CN disclosed
US-10106562-B2 Process for manufacture of gadofosveset trisodium monohydrate LANTHEUS MEDICAL IMAGING, INC. (US) 2018-10-23 US disclosed
CN-107663228-A Magnetic resonance imaging compound, magnetic resonance imaging agent and application and magnetic resonance imaging method employing 北京市神经外科研究所 2018-02-06 CN disclosed
US-20160016979-A1 PROCESS FOR MANUFACTURE OF GADOFOSVESET TRISODIUM MONOHYDRATE CITIZENS BANK, N.A. 2016-01-21 US disclosed
EP-2970140-A1 PROCESS FOR MANUFACTURE OF GADOFOSVESET TRISODIUM MONOHYDRATE Lantheus Medical Imaging, Inc. (US) 2016-01-20 EP disclosed
CN-105209439-A Process for manufacture of gadofosveset trisodium monohydrate LANTHEUS MEDICAL IMAGING INC 2015-12-30 CN disclosed
WO-2014160039-A1 PROCESS FOR MANUFACTURE OF GADOFOSVESET TRISODIUM MONOHYDRATE LANTHEUS MEDICAL IMAGING, INC. (US) 2014-10-02 WO disclosed
WO-2014160039-A1 PROCESS FOR MANUFACTURE OF GADOFOSVESET TRISODIUM MONOHYDRATE LANTHEUS MEDICAL IMAGING, INC. (US) 2014-10-02 WO disclosed
US-7927581-B2 For magnetic resonance imaging (MRI); peptide modified at its N- and its C-termini, independently, with a moiety comprising a metal chelate complex; specific binding affinity for fibrin; sufficient half-life in vivo Factor 1A, LLC (US) 2011-04-19 US disclosed
US-7238341-B2 Peptide-based multimeric targeted contrast agents EPIX PHARMACEUTICALS, INC. (US) 2007-07-03 US disclosed
US-7189879-B2 Process for the production of 1-hydroxymethyl-1,3,5-triazapentane, trihydrochloride SCHERING AG (DE) 2007-03-13 US disclosed
US-7189879-B2 Process for the production of 1-hydroxymethyl-1,3,5-triazapentane, trihydrochloride SCHERING AG (DE) 2007-03-13 US disclosed
US-7189879-B2 Process for the production of 1-hydroxymethyl-1,3,5-triazapentane, trihydrochloride SCHERING AG (DE) 2007-03-13 US disclosed
EP-1748977-A1 METHOD FOR PRODUCING 1-HYDROXYMETHYL-1,3,5-TRIAZAPENTANE, TRIHYDROCHLORIDE Schering Aktiengesellschaft (DE) 2007-02-07 EP disclosed
US-20060039861-A1 Peptide-based multimeric targeted contrast agents EPIX MEDICAL, INC., A DELAWARE CORPORATION 2006-02-23 US disclosed
US-20060014983-A1 Process for the production of 1-hydroxymethyl-1,3,5-triazapentane, trihydrochloride BAYER SCHERING PHARMA AKTIENGESELLSCHAFT (DE) 2006-01-19 US disclosed
WO-2005115968-A1 METHOD FOR PRODUCING 1-HYDROXYMETHYL-1,3,5-TRIAZAPENTANE, TRIHYDROCHLORIDE SCHERING AKTIENGESELLSCHAFT (DE) 2005-12-08 WO disclosed
US-20050074411-A1 Peptide-based multimeric targeted contrast agents EPIX MEDICAL, INC. A DELAWARE CORPORATION 2005-04-07 US disclosed